Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases
Słowa kluczowe
Abstrakcyjny
Opis
In developed counties Non-alcoholic fatty liver disease (NAFLD) becomes the most common cause of chronic liver disease , but its prevalence in developing countries like India is also increasing (10 -20%). Most of the patients are diagnosed clinically and by increased serum transaminase and fatty changes in liver on abdominal ultrasound. Till date, there is no US-FDA approved therapy for NAFLD but drugs like metformin, pioglitazone, sitagliptin, vildagliptin Vitamin E, silymarin, statins and ezetimibe have been studied along with life style modification. Life style modifications is the current modality of treatment of NAFLD. All the above-mentioned drugs have some beneficial effects with limited use due to its adverse effects in patients of NAFLD and the study results are non-conclusive. In this scenario, a safe hepatoprotective drug to be evaluated in NAFLD.
Alpha-lipoic acid (ALA) or 6,8-thioctic acid, is an endogenous molecule which functions as an important co-factor for various enzyme complexes in mitochondria and plays an important role in energy metabolism. ALA is a nutraceutical agent which also has hepatoprotective and anti-inflammatory effects. Previous animal studies proved the hepatoprotective effect of alpha lipoic acid on various animal models. Inflammatory liver injury involves the production of inflammatory mediators like nitric oxide and TNF-alpha. Alpha -Lipoic acid significantly inhibits production of nitric oxide and TNF-alpha. The reduced production of nitric oxide and TNF-alpha in Kupffer cells may be involved in the hepatoprotective action conveyed by alpha-lipoic acid.It has been proved that ALA has potent anti - inflammatory and anti- oxidant properties.
Insulin resistance is associated with impaired hepatic cell damage, intrahepatic cholestasis, atherogenic dyslipidaemia and fibrosis in patients of NAFLD. Daily treatment with ALA for 28 days significantly improved insulin sensitivity performance in mice by decreasing insulin resistance, IL-6 levels, acetylcholinesterase enzyme activity and oxidative stress in liver. Various studies have shown that the ALA can efficiently improve insulin sensitivity and reverse the insulin resistance. Cytokeratin 18 (CK 18) is released into circulation as a consequence of oxidative stress, hepatocyte apoptosis or inflammation in response to lipid metabolism in NAFLD. CK - 18 level is higher in insulin resistance.
ALA is a nutraceutic having anti-inflammatory and antioxidant effects and also increasing insulin sensitivity with lesser adverse effects. The relative scarcity of a promising therapy and non-conclusiveness of the previous studies open up an arena of further research using a nutraceutic in non-diabetic NAFLD. So, the present study is designed to evaluate safety and efficacy of ALA in non-diabetic NAFLD patients.
Daktyle
| Ostatnia weryfikacja: | 06/30/2020 |
| Pierwsze przesłane: | 07/09/2020 |
| Szacowana liczba przesłanych rejestracji: | 07/14/2020 |
| Wysłany pierwszy: | 07/16/2020 |
| Ostatnia aktualizacja przesłana: | 07/14/2020 |
| Ostatnia opublikowana aktualizacja: | 07/16/2020 |
| Rzeczywista data rozpoczęcia badania: | 07/31/2020 |
| Szacowana data zakończenia podstawowej działalności: | 08/30/2021 |
| Szacowana data zakończenia badania: | 12/30/2021 |
Stan lub choroba
Interwencja / leczenie
Drug: Placebo
Drug: Alphalipoic acid
Faza
Grupy ramion
| Ramię | Interwencja / leczenie |
|---|---|
| Placebo Comparator: Placebo Life style modification with the placebo will be given for 12 weeks | Drug: Placebo Lifestyle modification with placebo for 12 weeks |
| Experimental: Alphalipoic acid Life style modification with Alpha lipoic acid in a dose of 600mg twice daily will be prescribed orally for 12 weeks | Drug: Alphalipoic acid Lifestyle modification with Alphalipoic acid for 12 weeks |
Kryteria kwalifikacji
| Wiek kwalifikujący się do nauki | 18 Years Do 18 Years |
| Płeć kwalifikująca się do nauki | All |
| Przyjmuje zdrowych wolontariuszy | tak |
| Kryteria | Inclusion Criteria: - All patients diagnosed to have fatty liver grading 1, 2, 3 on abdominal ultrasound, mild to moderate elevation (<5 times elevated upper limit) of serum aminotransferase level. - Patients aged 18-65 years of either sex. - Treatment naïve patients or patients who had not taken any treatment for at least 4 weeks before inclusion Exclusion Criteria: - History of diabetes mellitus, decompensated liver disease, ascites, oesophageal varices. - Drug abusers and Alcoholics. - HBs Ag positive, Anti HCV and HIV, hereditary defects of iron, copper and alpha- 1 antitrypsin deficient patients. - Hypothyroidism, obstructive sleep apnoea, total parenteral nutrition, short bowel syndrome, pancreatoduodenal resection which are secondary causes of NAFLD. - Drug users such as corticosteroids, antiviral (nucleoside analogue), tetracycline, methotrexate, tamoxifen and amiodarone. - Patients who are taking any antihyperlipidemic and anti-diabetic agents. |
Wynik
Podstawowe miary wyników
1. Abdominal ultrasound [12 weeks]
Miary wyników wtórnych
1. Insulin resistance [12 weeks]
2. Lipid profile [12 weeks]
3. Levels of glutathione reductase [12 weeks]
4. levels of Cytokeratin-18 [12 weeks]
5. Levels of Alanine transaminase (ALT) [12 weeks]
6. Levels of Aspartate transaminase (AST) [12 weeks]
7. Levels of Alkaline phosphatase (ALP) [12 weeks]
8. Levels of Albumin and total protein. [12 weeks]
9. Levels of Bilirubin [12 weeks]
10. Levels of total protein [12 weeks]
11. Levels of Gamma-glutamyltransferase (GGT). [12 weeks]
12. Levels of L-lactate dehydrogenase (LDH). [12 weeks]
